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Alzheimer’s	Disease	is	the	most	common	form	of	dementia	and	can	cause	
problems	with	memory,	thinking	and	behavior.		It	is	the	sixth	leading	cause	of	
mortality	in	the	United	States	and	risk	factors	include	age,	family	history,	
genetics	and	new	research	even	shows	some	factors	that	we	have	control	over.	
Alzheimer’s	Disease	has	gained	a	lot	of	attention	and	about	ninety	percent	of	
what	we	know	about	this	disease	has	been	discovered	in	the	last	20	years	
(Alzheimer’s	Association,	2017).		I	chose	this	topic	because	Alzheimer’s	disease	
runs	in	my	family	and	I	used	to	work	at	a	nursing	home	on	the	Alzheimer’s	and	
Dementia	unit.	
Otterbein	University,	Westerville,	Ohio
Conclusion
Implications	for	Nursing	Care
Signs	&	Symptoms
The	signs	and	symptoms	of	Alzheimer’s	disease	can	vary	based	
on	each	patient	and	how	far	their	disease	has	progressed.	The	
classic	symptoms	of	this	disease	are	listed	below	and	some	
symptoms	based	on	stages	are	listed	above.
1.	Memory	loss	that	disrupts	daily	life
2.	Challenges	in	planning	or	solving	problems
3.	Difficulty	completing	tasks	at	home/work
4.	Confusion	with	time	and	place
5.	Trouble	understanding	visual	images	and	spatial	relationships
6.	Problems	with	speaking	or	writing
7.	Misplacing	things
8.	Poor	judgement
9.	Withdrawal	from	work	or	social	activities
10.	Changes	in	mood	or	personality
Increases	in	depressive	symptoms	and	functional	impairment	
occur	in	months	leading	up	to	AD	diagnoses.	(Gaugler,	Hovater,	
Roth,	Johnston…	2014,	p.110).
Underlying	Pathophysiology
Even	though	Alzheimer’s	disease	is	an	irreversible	brain	disorder	and	usually	
occurs	with	advanced	age	it	is	not	a	normal	part	of	aging.		This	disease	is	
named	after	Dr. Alois Alzheimer	who	in	1906	noticed	changes	in	the	brain	
tissue	of	a	woman	who	died	of	an	unusual	mental	illness	(National	Institute	
on	Aging,	2017).		Once	this	woman	died	Dr.	Alzheimer	examined	her	brain	
and	found	abnormal	clumps	and	tangled	bundles	of	fibers..		Alzheimer’s	
Disease	(AD)	is	a	progressive	type	of	dementia	that	involves	two	hallmarks:	
extracellular	amyloid	plaques	and	intracellular	neurofibrillary	tangles.		
Amyloid	plaques	consist	of	protein	beta	amyloid	which	produces	amyloid	
precursor	protein.	These	amyloid	plaques	are	believed	to	interfere	with	the	
brains	synaptic	activity	which	cause	neuron	dysfunction	and	cell	death..	
Neurofibrillary	tangles	consist	of	the	protein	tau,	that	maintains	the	structure	
of	the	nerve	cell,	and	when	phosphorylation	happens	it	prevents	this	protein	
from	working	effectively.	Brain	inflammation	and	oxidative	stress	are	also	
characteristic	in	Alzheimer’s	disease	(Alzheimer’s	Association,	2017)).		
Genome-wide	associated	studies	have	established	multiple	susceptible	genes	
and	mutations		in	early	and	late	Alzheimer’s	disease:
1.	Apolipoprotein	E	(APOE)	Gene	on	chromosome	19
2.	Abnormal	amyloid	precursor	protein	(APP)	on	chromosome	21
3.	Abnormal	presenilin 1	on	chromosome	14
4.	Abnormal	presenilin 2	on	chromosome	1	
Since	Alzheimer’s	is	a	neurodegenerative	disease	it	leads	to	cell	death	and	
tissue	loss	as	time	goes	on.	The	brain	will	begin	to	shrink	which	can	affect	
many	functions.	In	the	brain	of	someone	with	Alzheimer’s	the	cortex	will	
shrivel	overtime	and	damage	memory,	thinking	and	planning.	The	
hippocampus	which	is	located	in	the	cortex	is	severely	affected	and	does	
not	allow	the	patient	to	form	new	memories.		Ventricles	in	the	brain	get	
larger	as	seen	in	the	figure	above.	This	causes	more	fluid	filled	space	in	
the	brain.	Besides	the	build	up	of	amyloid	proteins	age	related	changes	
also	harm	neurons	that	can	contribute	to	further	damage.		These	can	
include	atrophy	to	different	parts	of	the	brain,	inflammation,	free	radical	
production	and	mitochondrial	dysfunction	(National	Institute	on	Aging,	
2017).	Drugs	used	in	the	treatment	of	Alzheimer’s	disease	are	designed	to	
fight	the	build-up	of	abnormal	amyloid	proteins.	Cholinesterase	inhibitors	
can	help	treat	the	cognitive	symptoms	of	this	disease.		While	these	
medications	cannot	stop	the	damage	of	Alzheimer’s	in	the	brain	cells	they	
can	help	decrease	or	stabilize	symptoms	by	affecting	certain	chemicals	
involved	in	carrying	messages	along	the	cells	in	the	brain	(Alzheimer’s	
Association,	2017).		Four	medications	are	currently	used	in	the	United	
States:
Donepezil	(Aricept)	used	for	all	stages
Rivastigmine (Exelon)	used	for	mild	to	moderate	stages
Galantamine (Razadyne)	used	for	mild	to	moderate	stages
Memantine (Namenda)	used	for	moderate	to	severe	stages
All	of	these	medications	are	cholinesterase	inhibitors	except	Namenda	
which	regulates	gluatamate and	helps	to	improve	mental	function	and	
perform	daily	living	tasks	(Alzheimer’s	Association,	2017)
Worldwide	public	health	crisis	is	
continuing	to	grow	due	to	the	
worlds	population	aging	and	lack	of	
effective	interventions.		Since	the	
baby	boomers	in	the	United	States	
are	getting	older	this	is	going	to	
create	a	serious	crisis	in	not	only	
care	but	cost.		The	United	States	has	
developed	the	National	Plan	to	
Address	Alzheimer’s	Disease	to	
provide	tools	for	clinicians,	assist	
caregivers	and	patients	with	AD,	
raise	public	awareness	and	to	
advance	research	(Fargo,	Aisen,	
Alber,	Au…	2014,	p.	430).	Main	focus	
points	of	the	United	States	National	
Plan	to	Address	Alzheimer’s	include:
1.	Development	of	targets	and	
interventions
2.	Drug	development	
3.	Development	of	
nonpharmacologic interventions
4.	Biomarkers	of	disease	progression
5.	Research
6.	Clinical	Trials
• 1	in	9	people	ages	65	and	older	are	diagnosed	with	Alzheimer’s	disease,	
one	third	of	people	85	years	and	older	have	the	diagnosis.		The	number	of	
cases	is	projected	to	triple	by	2050	(Warshaw &	Bragg,	2014,	p.633)		
• Early	Stage	of	Alzheimer’s	will	focus	on	diagnosis	support	and	
management	at	home.	Patients	usually	present	to	their	primary	care	
providers	to	be	evaluated	for	several	weekly	visits	involving	nurses,	social	
workers,	neurologists,	geriatrician	and	psychiatrist	(Warshaw &	Bragg,	
2014,	p.	634).		
• In	the	middle	stage	of	Alzheimer’s	nurses	will	notice	increase	symptoms	
and	patients	may	need	around-the-clock	supervision	due	to	cognitive	or	
functional	limitations.		Caregivers	may	begin	to	see	changes	in	the	
patients’	personality	and	mood.		
• The	last	stage	nurses	will	notice	progressive	cognitive	decline	and	
extensive	damage	to	the	brain.		It	is	crucial	that	nurses	that	are	helping	
patients	in	this	stage	also	support	family	members	in	making	difficult	
decisions	about	levels	and	type	of	care	provided.	
• Nurse	Practitioners	should	guide	care	with	individualized	plans	that	
account	for	each	patient’s	needs,	values	and	goals	(Warshaw &	Bragg,	
2014,	p.	638).		
• Primary	prevention	may	help	reduce	some	modifiable	risk	factors	for	
Alzheimer’s	disease.	
• The	main	modifiable	risk	factors	include	diabetes	mellitus,	midlife	
hypertension,	midlife	obesity,	physical	inactivity,	depression,	smoking	and	
low	educational	attainment	(Norton,	Matthews,	Barnes,	Yaffe…	2014,	
p.788).
Who	is	at	risk?
The	greatest	known	risk	factor	for	Alzheimer’s	is	advancing	age.		A	
majority	of	other	cases	occur	due	to	a	combination	of	hereditary	and	
genetics	(Alzheimer’s	Association,	2017).		Two	other	possible	precursors	
to	this	disease	include	head	injury	or	trauma	and	a	persons	heart	health.
